Actively Recruiting
68Ga-HA-DOTATATE PET/CT Imaging in Adults With Neuroendocrine Tumors
Led by Alberta Health services · Updated on 2023-01-05
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of 68Ga-HA-DOTATATE PET/CT imaging to diagnose somatostatin-positive neuroendocrine tumors compared to conventional imaging methods such as CT, MRI, 111 In-pentetreotide scans, and 18F-FDG PET/CT. The study aims to assess the usefulness of 68Ga-HA-DOTATATE in initial diagnosis, surveillance of completely removed tumors, and localization of functioning tumors like insulinoma and gastrinoma. Participants will receive an intravenous injection of 100-250 MBq of 68Ga-HA-DOTATATE. Imaging starts 45-90 minutes after the injection, followed by a CT scan for localization without moving the patient. The 68Ga-HA-DOTATATE PET/CT results will be compared to any prior imaging and pathology reports to evaluate its diagnostic utility. During the study, participants will undergo the PET/CT imaging procedure and provide informed consent. The research team will monitor the imaging results over five years to assess the diagnostic value of 68Ga-HA-DOTATATE PET/CT. Participants are expected to comply with study instructions and attend scheduled imaging sessions as part of this observational study.
CONDITIONS
Brief Title
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female. Females of child-bearing potential must have a negative pregnancy test if outside 10 days since last menstrual period
- Age 18 years or older
- Able and willing to follow instructions and comply with the protocol
- Provide written informed consent before participation
- Clinically suspected or biopsy-proven neuroendocrine tumor
You will not qualify if you...
- Nursing or pregnant females
- Age under 18 years
- Surgery in the area of interest within the last 2 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 5 years
Participants undergo 68Ga-HA-DOTATATE PET/CT imaging to evaluate neuroendocrine tumors and compare results with prior imaging and pathology.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Foothills Medical Center 1403 29 St NW
Calgary, Alberta, Canada, T2N 2T9
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here